Literature DB >> 30552634

In Schizophrenia, Increased Plasma IgM/IgA Responses to Gut Commensal Bacteria Are Associated with Negative Symptoms, Neurocognitive Impairments, and the Deficit Phenotype.

Michael Maes1,2,3, Buranee Kanchanatawan4, Sunee Sirivichayakul5, André F Carvalho6,7.   

Abstract

Increased gut permeability (leaky gut) with increased translocation of Gram-negative bacteria plays a role in the gut-brain axis through effects on systemic immune-inflammatory processes. Deficit schizophrenia is characterized by an immune-inflammatory response combined with a deficit in natural IgM antibodies to oxidative-specific epitopes (OSEs), which are a first-line defense against bacterial infections. This study measured plasma IgA/IgM responses to 5 Gram-negative bacteria in association with IgM responses to malondialdehyde (MDA) and azelaic acid in 80 schizophrenia patients (40 with the deficit syndrome and 40 without) and in 38 healthy controls. Deficit schizophrenia was characterized by significantly increased IgA responses to Hafnei alvei, Pseudomonas aeruginosa, Morganella morganii, and Klebsiella pneumoniae as compared with non-deficit schizophrenia. The presence of deficit schizophrenia was highly predicted by increased IgA responses to Pseudomonas putida and IgM responses to all five Gram-negative bacteria and lowered natural IgM to MDA and azelaic acid with a bootstrap area under the receiver operating characteristic curve of 0.960 (2000 random curves). A large proportion of the variance (41.5%) in the negative subscale score of the Positive and Negative Syndrome Scale was explained by the regression on IgA responses to K. pneumoniae and IgM responses to the five enterobacteria coupled with lowered IgM antibodies to azelaic acid. There were significant associations between IgA levels to Gram-negative bacteria and Mini-Mental State Examination, Boston naming test, Verbal Fluency, and Word List Memory test scores. These findings provide further evidence that deficit schizophrenia is a distinct phenotype of schizophrenia, which is characterized by an increased impact of Gram-negative commensal bacteria coupled with a deficit in natural IgM, pointing to aberrations in B1 cells. It is concluded that increased bacterial translocation and deficits in the compensatory immune-regulatory system (CIRS) may drive negative symptoms and neurocognitive impairments, which are hallmarks of deficit schizophrenia.

Entities:  

Keywords:  B1 cells; Immune; Inflammation; Natural IgM; Oxidative stress; Psychiatry; Psychosis; Schizophrenia; TRYCATs

Mesh:

Substances:

Year:  2018        PMID: 30552634     DOI: 10.1007/s12640-018-9987-y

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  13 in total

1.  Breakdown of the Paracellular Tight and Adherens Junctions in the Gut and Blood Brain Barrier and Damage to the Vascular Barrier in Patients with Deficit Schizophrenia.

Authors:  Michael Maes; Sunee Sirivichayakul; Buranee Kanchanatawan; Aristo Vodjani
Journal:  Neurotox Res       Date:  2019-05-10       Impact factor: 3.911

2.  High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments.

Authors:  Arafat Hussein Al-Dujaili; Rana Fadhil Mousa; Hussein Kadhem Al-Hakeim; Michael Maes
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

Review 3.  The Role of the Oral Microbiota Related to Periodontal Diseases in Anxiety, Mood and Trauma- and Stress-Related Disorders.

Authors:  María Martínez; Teodor T Postolache; Borja García-Bueno; Juan C Leza; Elena Figuero; Christopher A Lowry; Stefanie Malan-Müller
Journal:  Front Psychiatry       Date:  2022-01-27       Impact factor: 4.157

4.  First Episode Psychosis and Schizophrenia Are Systemic Neuro-Immune Disorders Triggered by a Biotic Stimulus in Individuals with Reduced Immune Regulation and Neuroprotection.

Authors:  Michael Maes; Kitiporn Plaimas; Apichat Suratanee; Cristiano Noto; Buranee Kanchanatawan
Journal:  Cells       Date:  2021-10-28       Impact factor: 6.600

Review 5.  The role of innate lymphoid cells (ILCs) in mental health.

Authors:  Tatiana Barichello
Journal:  Discov Ment Health       Date:  2022-02-07

6.  Consensus on potential biomarkers developed for use in clinical tests for schizophrenia.

Authors:  Ping Lin; Junyu Sun; Xiaoyan Lou; Dan Li; Yun Shi; Zhenhua Li; Peijun Ma; Ping Li; Shuzi Chen; Weifeng Jin; Shuai Liu; Qing Chen; Qiong Gao; Lili Zhu; Jie Xu; Mengyuan Zhu; Mengxia Wang; Kangyi Liang; Ling Zhao; Huabin Xu; Ke Dong; Qingtian Li; Xunjia Cheng; Jinghong Chen; Xiaokui Guo
Journal:  Gen Psychiatr       Date:  2022-02-23

7.  Increased Levels of Plasma Tumor Necrosis Factor-α Mediate Schizophrenia Symptom Dimensions and Neurocognitive Impairments and Are Inversely Associated with Natural IgM Directed to Malondialdehyde and Paraoxonase 1 Activity.

Authors:  Michael Maes; Sunee Sirivichayakul; Andressa Keiko Matsumoto; Annabel Maes; Ana Paula Michelin; Laura de Oliveira Semeão; João Victor de Lima Pedrão; Estefania G Moreira; Decio S Barbosa; Michel Geffard; Andre F Carvalho; Buranee Kanchanatawan
Journal:  Mol Neurobiol       Date:  2020-02-10       Impact factor: 5.590

8.  Inflammatory Pathways in Psychiatric Disorders: The case of Schizophrenia and Depression.

Authors:  Tami Feng; Ashutosh Tripathi; Anilkumar Pillai
Journal:  Curr Behav Neurosci Rep       Date:  2020-07-26

Review 9.  Schizophrenia, the gut microbiota, and new opportunities from optogenetic manipulations of the gut-brain axis.

Authors:  Enrico Patrono; Jan Svoboda; Aleš Stuchlík
Journal:  Behav Brain Funct       Date:  2021-06-22       Impact factor: 3.759

Review 10.  Gut dysbiosis in severe mental illness and chronic fatigue: a novel trans-diagnostic construct? A systematic review and meta-analysis.

Authors:  Jenelle Marcelle Safadi; Alice M G Quinton; Belinda R Lennox; Philip W J Burnet; Amedeo Minichino
Journal:  Mol Psychiatry       Date:  2021-02-08       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.